Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, Peter C., Boss, David S., Yap, Timothy A., Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J., Ashworth, Alan, Carmichael, James, Kaye, Stan B., Schellens, Jan H.M., de Bono, Johann S.·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0900212

Cited by (1,012)

Items 601–700 of 1,012

  1. Portrait of a cancer: mutational signature analyses for cancer diagnostics
    Van Hoeck, Arne, Tjoonk, Niels H., van Boxtel, Ruben, Cuppen, Edwin · 2019 · BMC Cancer
  2. Targeting Cancer with a Lupus Autoantibody
    James E. Hansen, Grace Chan, Yanfeng Liu, Denise Campisi Hegan, S. Dalal, Eloise V. Dray, Youngho Kwon, Yuekang Xu, Xiaohua Xu, Elizabeth Peterson-Roth et al. · 2012 · Science Translational Medicine
  3. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
    Florentia Fostira, Marianthi Tsitlaidou, CHRISTOS A. PAPADIMITRIOU, Maroulio Pertesi, Eleni T. Timotheadou, Alexandra V. Stavropoulou, Stavros Glentis, Evangelos Bournakis, Mattheos Bobos, Dimitrios G. Pectasides et al. · 2012 · Breast Cancer Research and Treatment
  4. The Role of Genetic Markers in the Management of Prostate Cancer
    Atish Dipankar Choudhury, Rosalind A. Eeles, Stephen J. Freedland, William B. Isaacs, Mark M. Pomerantz, Jack A. Schalken, Teuvo L.J. Tammela, Tapio Visakorpi · 2012 · European Urology
  5. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
    Rebeca Lozano, Elena Castro, Isabel M. Aragón, Ylenia Cendón, Carlo Cattrini, Pedro Pablo Lopez-Casas, David Olmos · 2020 · British Journal of Cancer
  6. The context-specific role of germline pathogenicity in tumorigenesis
    Preethi Srinivasan, Chaitanya Bandlamudi, Philip Jonsson, Yelena M. Kemel, Shweta S. Chavan, Allison L. Richards, Alexander V. Penson, Craig M. Bielski, Christopher John Fong, Aijazuddin Syed et al. · 2021 · Nature Genetics
  7. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
    Sidrah Shah, Rachelle Rachmat, Synthia Enyioma, Aruni Ghose, Antonios Revythis, Stergios Boussios · 2021 · International Journal of Molecular Sciences
  8. Perspectives on the development of imatinib and the future of cancer research
    Brian J. Druker · 2009 · Nature Medicine
  9. Molecular Pathways: Targeting PARP in Cancer Treatment
    Khanh T Do, Alice P. Chen · 2012 · Clinical Cancer Research
  10. Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
    Cantor, Sharon B, Guillemette, Shawna · 2011 · Future Oncology
  11. Pharmacologic characterization of fluzoparib, a novel poly( ADP ‐ribose) polymerase inhibitor undergoing clinical trials
    Lei Wang, Changyong Yang, Chengying Xie, Jiahua Jiang, Mingzhao Gao, Fu Li, Yun Li, Xubin Bao, Haoyu Fu, Liguang Lou · 2019 · Cancer Science
  12. Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine
    Ólafur Andri Stefánsson, Manel Esteller · 2013 · American Journal Of Pathology
  13. Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?
    Michael C. Haffner, Angelo Michael De Marzo, Alan Keith Meeker, William G. Nelson, Srinivasan Yegnasubramanian · 2011 · Clinical Cancer Research
  14. Making the best of PARP inhibitors in ovarian cancer
    Susana N. Banerjee, Stan B. Kaye, Alan Ashworth · 2010 · Nature Reviews Clinical Oncology
  15. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells
    Michael S. Goldberg, Deyin Xing, Yin Ren, Sandra Oršulić, Sangeeta N. Bhatia, Phillip A. Sharp · 2010 · Proceedings of the National Academy of Sciences
  16. Use of molecular markers for predicting therapy response in cancer patients
    Michael Joe Duffy, Norma O’Donovan, John Paul Crown · 2010 · Cancer Treatment Reviews
  17. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
    Sophie C. Postel-Vinay, Sandrine Aspeslagh, Émilie Lanoy, Caroline Robert, Jean‐Charles Soria, Aurélien Marabelle · 2015 · Annals of Oncology
  18. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
    Tarra Evans, Ursula A. Matulonis · 2017 · Therapeutic Advances in Medical Oncology
  19. Olaparib
    Bochum, Sylvia, Berger, Stephanie, Martens, Uwe M. · 2018 · Recent Results in Cancer Research
  20. Flavonoids as inhibitors of human CD38
    Esther Kellenberger, Isabelle Kuhn, Francis J. Schuber, Hélène Muller‐Steffner · 2011 · Bioorganic & Medicinal Chemistry Letters
  21. Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy
    K. Aziz, Somaira Nowsheen, Gabriel E. Pantelias, George E. Iliakis, Vassilis G. Gorgoulis, Alexandros G. Georgakilas · 2011 · Pharmacology & Therapeutics
  22. Visualization of a DNA-PK/PARP1 complex
    Laura Spagnolo, Jody Barbeau, Nicola J. Curtin, Edward P. Morris, Laurence H. Pearl · 2012 · Nucleic Acids Research
  23. Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Justin R. Cidado, Ben Ho Park · 2012 · Journal of Mammary Gland Biology and Neoplasia
  24. Searching for synthetic lethality in cancer
    Rachel Brough, Jessica R. Frankum, Sara Costa-Cabral, Christopher J. Lord, Alan Ashworth · 2011 · Current Opinion in Genetics & Development
  25. Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
    Timothy Anthony Yap, Paul Workman · 2011 · The Annual Review of Pharmacology and Toxicology
  26. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
    Kenta Masui, Beatrice Gini, J. Wykosky, Ciro Zanca, Paul S. Mischel, Frank B. Furnari, Webster K. Cavenee · 2013 · Carcinogenesis
  27. 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
    Natalia Issaeva, Huw D. Thomas, Tatjana Djurenovic, Janneke E. Jaspers, Ivaylo Stoimenov, Suzanne Kyle, Nicholas Pedley, Ponnari Gottipati, Rafal Zur, Kate M. Sleeth et al. · 2010 · Cancer Research
  28. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
    Ciara Catherine O'Sullivan, Dominic Himchan Moon, Elise C. Kohn, Jung Min Lee · 2014 · Frontiers in Oncology
  29. Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement
    Benjamin H. Lok, Simon N. Powell · 2012 · Clinical Cancer Research
  30. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation
    Tatiana V. Gorodnova, Анна Петровна Соколенко, Alexandr O. Ivantsov, Aglaya G. Iyevleva, Evgeny N. Suspitsin, Светлана Николаевна Алексахина, Grigoriy A. Yanus, Alexandr V. Togo, S. Ya. Maximov, Евгений Наумович Имянитов · 2015 · Cancer Letters
  31. Charting the Landscape of Tandem BRCT Domain–Mediated Protein Interactions
    Nicholas T. Woods, Rafael Dias Mesquita, Michael Sweet, Marcelo Alex Carvalho, Xueli Li, Yun Liu, Huey Nguyen, Charles E. Thomas, Edwin S. Iversen, Sylvia M. Marsillac et al. · 2012 · Science Signaling
  32. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials
    Jian Zhou, Li Jin Feng, Xi Zhang · 2017 · Drug Design Development and Therapy
  33. DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage
    Thom G. A. Reuvers, Roland Kanaar, Julie Nonnekens · 2020 · Cancers
  34. Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review
    S. Hager, Christoph Jakob Ackermann, Markus Joerger, Silke Gillessen, Aurelius Gabriel Omlin · 2016 · Annals of Oncology
  35. Cancer Interception
    Elizabeth Helen Blackburn · 2011 · Cancer Prevention Research
  36. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
    Gianluca Del Conte, Cristiana Sessa, Roger von Moos, Lucia Viganò, Tiziana Digena, Alberta Locatelli, Elisa Gallerani, Angelica Fasolo, Anna Tessari, Richard L. Cathomas et al. · 2014 · British Journal of Cancer
  37. Synthetic lethal approaches to breast cancer therapy
    Farah L. Rehman, Christopher J. Lord, Alan Ashworth · 2010 · Nature Reviews Clinical Oncology
  38. ATM Kinase Is Required for Telomere Elongation in Mouse and Human Cells
    Stella S. Lee, Craig L. Bohrson, Alexandra M. Pike, Sarah J. Wheelan, Carol W. Greider · 2015 · Cell Reports
  39. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
    Yao Xiong, Yin Guo, Ye Liu, Hexiang Wang, Wenfeng Gong, Yong Liu, Xing Wang, Yajuan Gao, Fenglong Yu, Dan Su et al. · 2020 · Neoplasia
  40. Targeted therapy for triple‐negative breast cancer: Where are we?
    Michael Joe Duffy, Patricia M. McGowan, John Paul Crown · 2012 · International Journal of Cancer
  41. Targeting DNA Replication Stress for Cancer Therapy
    Zhang, Jun, Dai, Qun, Park, Dongkyoo, Deng, Xingming · 2016 · Genes
  42. Germline Mutations in DNA Repair Genes Predispose Asbestos-Exposed Patients to Malignant Pleural Mesothelioma
    Betti, Marta, Casalone, Elisabetta, Ferrante, Daniela, Aspesi, Anna, Morleo, Giulia, Biasi, Alessandra, Sculco, Marika, Mancuso, Giuseppe, Guarrera, Simonetta, Righi, Luisella et al. · 2017 · Cancer Letters
  43. New perspectives on targeted therapy in ovarian cancer
    Jermaine Ian George Coward, Kathryn Middleton, Felicity Murphy · 2015 · International Journal of Women s Health
  44. Synthetic lethality: a framework for the development of wiser cancer therapeutics
    William G. Kaelin · 2009 · Genome Medicine
  45. Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma
    Erin Michelle Parry, Dustin L. Gable, Susan E. Stanley, Sara E. Khalil, Valentin Antonescu, Liliana Florea, Mary Y. Armanios · 2017 · Journal of Thoracic Oncology
  46. Recent trends in the management of advanced prostate cancer
    Chad Ryan Ritch, Michael S. Cookson · 2018 · F1000Research
  47. Role of poly(ADP‐ribose) polymerases in the regulation of inflammatory processes
    Péter Bai, László Virág · 2012 · FEBS Letters
  48. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer
    Füredi, András, Szebényi, Kornélia, Tóth, Szilárd, Cserepes, Mihály, Hámori, Lilla, Nagy, Veronika, Karai, Edina, Vajdovich, Péter, Imre, Tímea, Szabó, Pál et al. · 2017 · Journal of Controlled Release
  49. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
    J. C. Bendell, Eileen Mary O'Reilly, Mark Ross Middleton, Ian Chau, Howard S. Höchster, Anitra Fielding, Wendy Burke, Howard A. Burris · 2015 · Annals of Oncology
  50. Therapies for triple negative breast cancer
    Eleni Andreopoulou, Sarah J. Schweber, Joseph A. Sparano, Hayley M. McDaid · 2015 · Expert Opinion on Pharmacotherapy
  51. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
    Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., Halmos, B. · 2013 · Carcinogenesis
  52. Subtypes of familial breast tumours revealed by expression and copy number profiling
    kConFab Investigators, Waddell, Nic, Arnold, Jeremy, Cocciardi, Sibylle, da Silva, Leonard, Marsh, Anna, Riley, Joan, Johnstone, Cameron N., Orloff, Mohammed, Assie, Guillaume et al. · 2010 · Breast Cancer Research and Treatment
  53. The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment
    Monica Nancy Fornier, P. Fumoleau · 2011 · The Breast Journal
  54. Taming the dragon: genomic biomarkers to individualize the treatment of cancer
    Ian J. Majewski, René Bernards · 2011 · Nature Medicine
  55. Cancer–testis antigen expression in triple-negative breast cancer
    Giuseppe Curigliano, Giuseppe Viale, Mariacristina Ghioni, Achim A. Jungbluth, Vincenzo Bagnardi, Giulio C. Spagnoli, A.M. Neville, Franco Nolè, Nicole Rotmensz, A. Goldhirsch · 2010 · Annals of Oncology
  56. BRD4 facilitates replication stress-induced DNA damage response
    Jingwen Zhang, Austin M. Dulak, Maureen Mertens Hattersley, Brandon S. Willis, Jenni Nikkilä, Anderson T. Wang, Alan Lau, Corinne Reimer, Michael J. Zinda, Stephen E. Fawell et al. · 2018 · Oncogene
  57. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
    Jingyan Yi, Chongya Liu, Zhiwei Tao, Min Wang, Yaxun Jia, Xiaolin Sang, Lanlin Shen, Yijue Xue, Kui Jiang, Fuwen Luo et al. · 2019 · EBioMedicine
  58. MYC and therapy resistance in cancer: risks and opportunities
    Giulio Donati, Bruno B. Amati · 2022 · Molecular Oncology
  59. FBH1 Helicase Disrupts RAD51 Filaments in Vitro and Modulates Homologous Recombination in Mammalian Cells
    Jitka Šimandlová, Jennifer Zagelbaum, Miranda Payne, Wai Kit Chu, Igor Shevelev, Katsuhiro Hanada, Sujoy Chatterjee, Dylan A. Reid, Ying Liu, Pavel Janščák et al. · 2013 · Journal of Biological Chemistry
  60. PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA
    Emily N. Risdon, Cindy H. Chau, Douglas K. Price, Oliver A. Sartor, William Douglas Figg · 2020 · The Oncologist
  61. Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition
    Francesca Cavallo, Grazia Graziani, Cristina Antinozzi, Darren Richard Feldman, Jane Houldsworth, George J. Bosl, Raju S. K. Chaganti, Mary Ellen Moynahan, Maria Jasin, Marco Barchi · 2012 · PLoS ONE
  62. The role of BRCA mutation testing in determining breast cancer therapy
    Alison H. Trainer, Craig R. Lewis, Kathy Tucker, Bettina Meiser, Michael Leonard Friedlander, Robyn Lynne Ward · 2010 · Nature Reviews Clinical Oncology
  63. Molecular landscape of pancreatic cancer: implications for current clinical trials
    Gregory M. Heestand, Razelle Kurzrock · 2015 · Oncotarget
  64. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer
    Denis Velic, Anthony M. Couturier, Maria Ferreira, Amélie Rodrigue, Guy G. Poirier, Fabrice Fleury, Jean‐Yves Masson · 2015 · Biomolecules
  65. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
    Maha Hussain, Michael Anthony Carducci, Susan F. Slovin, Jeremy Paul Cetnar, Jiang X. Qian, Evelyn Mary McKeegan, Marion Refici-Buhr, Brenda Chyla, Stacie Peacock Shepherd, Vincent L. Giranda et al. · 2014 · Investigational New Drugs
  66. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
    TNT Trial TMG, BCSC (UK), Lindsay B. Robertson, Helen Hanson, S. Seal, Margaret Warren-Perry, Deborah Hughes, Imran Howell, Clare Turnbull, Richard S. Houlston, Susan Shanley et al. · 2012 · British Journal of Cancer
  67. Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials
    Arif Manji, Irene Braña, Eitan Amir, GEORGE A. TOMLINSON, Ian F. Tannock, Philippe Lucien Bedard, Amit M. Oza, Lillian L. Siu, Albiruni R. Abdul Razak · 2013 · Journal of Clinical Oncology
  68. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies
    Berina Eppink, Przemek M. Krawczyk, Jan Stap, Roland Kanaar · 2012 · International Journal of Hyperthermia
  69. Biomarker Studies in Early Detection and Prognosis of Breast Cancer
    Gang Li, Jing Hu, Guohong Hu · 2017 · Advances in experimental medicine and biology
  70. Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21
    Ali Hussain, Véronique Voisin, Stephanie Poon, Christina Karamboulas, Ngoc H.B. Bui, Jalna Meens, Julia Dmytryshyn, Victor W. Ho, Kwan Ho Tang, Joshua Paterson et al. · 2020 · The Journal of Experimental Medicine
  71. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers
    Mieke Kriege, Agnes Jager, Maartje J. Hooning, Elisabeth Huijskens, Jannet Blom, Carolien H. M. van Deurzen, Marijke Bontenbal, Johanna Margriet Collée, Marian B. E. Menke‐Pluijmers, John W.M. Martens et al. · 2011 · Cancer
  72. Appraising iniparib, the PARP inhibitor that never was—what must we learn?
    Mateo, Joaquin, Ong, Michael, Tan, David S. P., Gonzalez, Michael A., de Bono, Johann S. · 2013 · Nature Reviews Clinical Oncology
  73. Deciphering the BRCA1 Tumor Suppressor Network
    Qinqin Jiang, Roger A. Greenberg · 2015 · Journal of Biological Chemistry
  74. γ-H2AX and other histone post-translational modifications in the clinic
    Christophe E. Redon, Urbain Weyemi, Palak R. Parekh, Dejun Huang, Allison S. Burrell, William M. Bonner · 2012 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
  75. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling
    Nan Li, Yifan Wang, Shinya Neri, Yuanli Zhen, Lon Wolf R. Fong, Yawei Qiao, Xu Li, Zhen Chen, CLIFFORD C. STEPHAN, Weiye Deng et al. · 2019 · Nature Communications
  76. Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes
    Sidrah Shah, Alison Cheung, Mikolaj Kutka, Matin Sheriff, Stergios Boussios · 2022 · International Journal of Environmental Research and Public Health
  77. BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
    Xin Li, Lee Zou · 2024 · Journal of Clinical Investigation
  78. The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis
    Chaoyang Sun, Na Li, Dong Ding, Danhui Weng, Meng Li, Gang Chen, Ding Ma · 2014 · PLoS ONE
  79. Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
    Christina M. Annunziata, Joyce O’Shaughnessy · 2010 · Clinical Cancer Research
  80. Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
    Chengzhi Xie, Christina Diane Drenberg, Holly J. Edwards, J. Timothy Caldwell, Wei Chen, Hiroto Inaba, Xuelian Xu, Steven A. Buck, Jeffrey Warren Taub, Sharyn D. Baker et al. · 2013 · PLoS ONE
  81. Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase
    Mark S. Dunstan, Eva Barkauskaite, Pierre Lafite, Claire E. Knezevic, Amy Brassington, Marijan Ahel, Paul J. Hergenrother, David Leys, Ivan Ahel · 2012 · Nature Communications
  82. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
    Charles Ferté, Fabrice André, Jean‐Charles Soria · 2010 · Nature Reviews Clinical Oncology
  83. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
    Maria Saveria Gilardini Montani, Andrea Prodosmo, Venturina Stagni, Dania Merli, Laura Monteonofrio, Veronica Gatti, Maria Pia Gentileschi, Daniela Barilà, Silvia Soddu · 2013 · Journal of Experimental & Clinical Cancer Research
  84. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers
    Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Lovise Mæhle, Dag Erik Undlien, Jan Norum, Ellen Schlichting · 2017 · BMC Cancer
  85. Neurofibromin and suppression of tumorigenesis: beyond the GAP
    Juan Mo, Stefanie L. Moye, Renée M. McKay, Lu Q. Le · 2022 · Oncogene
  86. DNA Damage, DNA Repair and Cancer
    Carol Bernstein, Anil R., Valentine Nfongen Nfonsam, Harris Bernstei · 2013 · InTech eBooks
  87. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1
    Sean M. Vance, Erqi Liu Pollom, Lili Zhao, Joshua D. Parsels, Leslie A. Parsels, Jeffery L. Brown, Jonathan Maybaum, Theodore Steven Lawrence, Meredith Ann Morgan · 2011 · Cell Cycle
  88. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury
    Partha Mukhopadhyay, Béla Horváth, Malek Kechrid, Galin Tanchian, Mohanraj Rajesh, Amarjit Singh Naura, A. Hamid Boulares, Pál Pacher · 2011 · Free Radical Biology and Medicine
  89. Regulation of Recombination and Genomic Maintenance
    Wolf‐Dietrich Heyer · 2015 · Cold Spring Harbor Perspectives in Biology
  90. Online Tool to Guide Decisions forBRCA1/2Mutation Carriers
    Allison W. Kurian, Diego F. Muñoz, Peter Rust, Elizabeth A. Schackmann, Michael H. Smith, Lauren D. Clarke, Meredith A. Mills, Sylvia K. Plevritis · 2012 · Journal of Clinical Oncology
  91. Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers
    Sarah A. Martin, Madeleine Hewish, David Sims, Christopher J. Lord, Alan Ashworth · 2011 · Cancer Research
  92. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
    Giovanni Grignani, Lorenzo D’Ambrosio, Ymera Pignochino, Emanuela Palmerini, Massimo Zucchetti, Paola Boccone, Sandra Aliberti, Silvia Stacchiotti, Rossella Bertulli, Raimondo Piana et al. · 2018 · The Lancet Oncology
  93. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
    Hexiang Wang, Bo Xu Ren, Ye Liu, Beibei Jiang, Yin Guo, Min Wei, Lusong Luo, Xianzhao Kuang, Ming Qiu, Lei Lv et al. · 2020 · Journal of Medicinal Chemistry
  94. Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
    Olivia S. Chao, Oscar B. Goodman · 2014 · Molecular Cancer Research
  95. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer
    Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy L. Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan Hendrik Beumer, Larissa A. Korde et al. · 2016 · Clinical Cancer Research
  96. DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy
    Benjamin J. Moeller, John S. Yordy, Michelle D. Williams, Uma P. Giri, Uma Raju, David P. Molkentine, Lauren A. Byers, John Victor Heymach, Michael D. Story, J. Jack Lee et al. · 2011 · Clinical Cancer Research
  97. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
    Camille Catherine Gunderson, Kathleen N. Moore · 2015 · Future Oncology
  98. Precision medicine in pediatric oncology: Lessons learned and next steps
    Rajen J. Mody, John R. Prensner, Jessica N. Everett, Donald Williams Parsons, Arul M. Chinnaiyan · 2016 · Pediatric Blood & Cancer
  99. Chemotherapy in epithelial ovarian cancer
    Sandro Pignata, L. Cannella, Davide Leopardo, Carmela Pisano, Giovanni Salvatore Bruni, Gaetano Facchini · 2011 · Cancer Letters
  100. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
    David R. Fogelman, Robert A. Wolff, Scott Kopetz, Milind M. Javle, C. R. Bradley, Isabel Mok, Fernando Cabanillas, James L. Abbruzzese · 2011 · PubMed